Upregulation of the long noncoding RNA GJA9‐MYCBP and PVT1 is a potential diagnostic biomarker for acute lymphoblastic leukemia

• Published in: Cancer reports Vol. 7; no. 7; pp. e2115 - n/a
• Main Authors: Shahamiri, Kamal, Alghasi, Arash, Saki, Najmaldin, Teimori, Hossein, Kaydani, Gholam Abbas, sheikhi, Setare
• Format: Journal Article
• Language: English
• Published: Wiley 01.07.2024
• Subjects: acute lymphoblastic leukemia; LncRNA GJA9‐MYCBP; PVT1
• ISSN: 2573-8348; 2573-8348
• DOI: 10.1002/cnr2.2115

Background Acute lymphoblastic leukemia (ALL) is the most common type of blood cancer in children. Aberrant expression of long noncoding RNAs (lncRNAs) may set stages for ALL development. LncRNAs are emerging as a novel diagnostic and prognostic biomarker for ALL. Herein, we aimed to evaluate the expression of lncRNA GJA9‐MYCBP and PVT1 in blood samples of ALL and healthy individuals. Methods As a case–control study, 40 pairs of ALL and healthy individual samples were used. The expression of MYC and each candidate lncRNA was measured using quantitative real‐time PCR. Any possible association between the expression of putative noncoding RNAs and clinicopathological characteristics was also evaluated. Results LncRNA GJA9‐MYCBP and PVT1 were significantly upregulated in ALL samples compared with healthy ones. Similarly, mRNA levels of MYC were increased in ALL samples than control ones. Receiver operating characteristic curve analysis indicated a satisfactory diagnostic efficacy (p‐value <.0001), suggesting that lncRNA GJA9‐MYCBP and PVT1 may serve as a diagnostic biomarker for ALL. Linear regression analysis unveiled positive correlations between the expression level of MYC and lncRNA GJA9‐MYCBP and PVT1 in ALL patients (p‐values <.01). Conclusions In this study, we provided approval for the clinical diagnostic significance of lncRNA GJA9‐MYCBP and PVT1that their upregulations may be a diagnostic biomarker for ALL.